← All trials
NCT03347279
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 23, 2017
- Primary completion
- Sep 18, 2020
- Completion date
- Sep 18, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 1060
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- AstraZenecaLead sponsor
- AmgenCollaborator
- Royal Brompton Hospital, United KingdomOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.